Stimuli responsive nanosonosensitizers for sonodynamic therapy

Z Jiang, W **ao, Q Fu - Journal of Controlled Release, 2023 - Elsevier
Sonodynamic therapy (SDT) has gained significant attention in the treatment of deep tumors
and multidrug-resistant (MDR) bacterial infections due to its high tissue penetration depth …

Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways

Z **e, M Zhao, C Yan, W Kong, F Lan… - Cell Death & …, 2023 - nature.com
Cathepsin B (CatB), a cysteine protease, is primarily localized within subcellular endosomal
and lysosomal compartments. It is involved in the turnover of intracellular and extracellular …

Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance

Q Shi, Q Shen, Y Liu, Y Shi, W Huang, X Wang, Z Li… - Cancer cell, 2022 - cell.com
How glucose metabolism remodels pro-tumor functions of tumor-associated macrophages
(TAMs) needs further investigation. Here we show that M2-like TAMs bear the highest …

Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer

K Shitara, YJ Bang, S Iwasa, N Sugimoto… - … England Journal of …, 2020 - Mass Medical Soc
Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments

T Sun, C Jiang - Advanced drug delivery reviews, 2023 - Elsevier
Drug delivery systems (DDS) triggered by local microenvironment represents the state-of-art
of nanomedicine design, where the triggering hallmarks at intracellular and subcellular …

[HTML][HTML] Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

CA Powell, S Modi, H Iwata, S Takahashi, EF Smit… - ESMO open, 2022 - Elsevier
Introduction This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd)
monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in …

Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

S Modi, C Saura, T Yamashita, YH Park… - … England Journal of …, 2020 - Mass Medical Soc
Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

[HTML][HTML] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis …

SM Swain, M Nishino, LH Lancaster, BT Li… - Cancer treatment …, 2022 - Elsevier
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …

Fluorogenic probes for disease-relevant enzymes

J Zhang, X Chai, XP He, HJ Kim, J Yoon… - Chemical Society …, 2019 - pubs.rsc.org
Traditional biochemical methods for enzyme detection are mainly based on antibody-based
immunoassays, which lack the ability to monitor the spatiotemporal distribution and, in …

Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery

MK Shim, S Yang, IC Sun, K Kim - Advanced drug delivery reviews, 2022 - Elsevier
As immunogenic cell death (ICD) inducers initiating antitumor immune responses, certain
chemotherapeutic drugs have shown considerable potential to reverse the …